Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

The fall and rise of Group A Streptococcus diseases

We overview the changing epidemiology of Group A Streptococcus infections and the genetic alterations that accompany the emergence of Group A Streptococcus strains

Research

Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational study

We examined the impact of introducing a dedicated team to OPAT, to define the role of increased medical oversight in improving patient outcomes in this cohort.

Research

Burden of skin disease in two remote primary healthcare centres in northern and central Australia

Skin infections are an under-appreciated and dominant reason for presentation to primary healthcare centres in these indigenous communities

Research

Lessons learned from a hospital-wide review of blood stream infections for paediatric central line-associated blood stream infection prevention

Health care-associated bacteraemia has a significant impact on child health, exceeding the number of community-acquired bacteraemia at our hospital

Research

Infection characteristics and treatment of Staphylococcus aureus bacteraemia at a tertiary children's hospital

There is a wide spectrum of disease severity in paediatric Staphylococcus aureus bacteraemia

Research

A Retrospective case-series of children with bone and joint infection from northern Australia

We report osteomyelitis incidence in indigenous children of northern Australia is amongst the highest reported in the world

Research

Searching for Strep A in the clinical environment during a human challenge trial: a sub-study protocol

Streptococcus pyogenes (also known as group A Streptococcus , Strep A) is an obligate human pathogen with significant global morbidity and mortality. Transmission is believed to occur primarily between individuals via respiratory droplets, but knowledge about other potential sources of transmission via aerosols or the environment is limited. Such knowledge is required to design optimal interventions to control transmission, particularly in endemic settings.

Research

Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trial

Combination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data, with no previous randomized controlled trials (RCTs).